4 results about "Genetic screen" patented technology

The invention provides compositions and methods for performing mammalian cell genetics, e.g., genetic screens, using near-haploid cells. The invention further provides genes and gene products isolated using the inventive methods and methods of use thereof.

The invention discloses application of a reagent for detecting SCN2B and / or SCN4B gene mutation in preparation of a hereditary arrhythmia detection product. According to the present invention, through the dual detection system combining whole exon sequencing with Sanger sequencing verification, the accurate capture of the pathogenic mutation such as SCN2B-R28Q / Y69H / P210L and SCN4B-T211M is achieved, and the problem that only SCN5A is determined as the main pathogenic gene in the clinical diagnosis of J wave syndrome (JWS) at present, and the gene detection of about 70-80% of patients is negative is solved. Wherein the three missense mutations of the SCN2B and the SCN4B-T211M variation are reported in the JWS for the first time, and the SCN4B is clear as the JWS pathogenic gene for the first time, so that the pathogenic gene spectrum of the JWS is obviously expanded. A detection product developed on the basis of the method can realize early accurate diagnosis, provide personalized risk assessment (such as sudden death early warning induced by fever) for patients, guide genetic screening of family members and remarkably improve clinical diagnosis and treatment efficiency.

The application discloses application of a reagent for detecting SCN2B and / or SCN4B gene mutation in preparation of a genetic arrhythmia detection product. Through a double detection system of whole exon sequencing combined with Sanger sequencing verification, the application realizes accurate capture of pathogenic mutations such as SCN2B-R28Q / Y69H / P210L and SCN4B-T211M, and solves the difficulty that only SCN5A is confirmed as a main pathogenic gene in the current clinical diagnosis of J wave syndrome (JWS), and about 70%-80% of patients have gene detection negative. The three missense mutations of SCN2B and the SCN4B-T211M variation are reported for the first time in JWS, and SCN4B is confirmed as a pathogenic gene of JWS for the first time, which significantly expands the pathogenic gene spectrum of JWS. The detection product developed based on this can realize early accurate diagnosis, provide personalized risk assessment (such as early warning of sudden death induced by fever) for patients, and guide genetic screening of family members, and significantly improves the clinical diagnosis and treatment efficiency.

The application discloses a reagent for detecting long fragment deletion mutation of an FHOD3 gene and application thereof, and belongs to the technical field of biological medicine. The reagent comprises nucleic acid molecules specifically recognizing long fragment deletion mutation of an intron starting region of the FHOD3 gene, in particular primers and probes for deletion mutation of the 12th-14th exon and / or deletion mutation of the 15th exon. The application first discovers and verifies the two pathogenic deletion mutations closely related to hypertrophic cardiomyopathy. In cooperation with a microdroplet digital PCR technology, the reagent has a sensitivity of 99%, a specificity of more than 95%, good repeatability, and an accuracy of 95%-99%. The new detection rate reaches 40% in a patient family with a negative result of previous whole-exome sequencing, effectively making up for the deficiency that the prior art cannot detect long fragment deletion in an intron starting region, and the reagent is suitable for gene diagnosis, family genetic screening and genetic consultation of hypertrophic cardiomyopathy.